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GLI pathogenesis-related 1 (GLIPR1) was previously identified as an epigenetically regu-
lated tumor suppressor in prostate cancer and, conversely, an oncoprotein in glioma. More
recently, GLIPR1 was shown to be differentially expressed in other cancers including ovar-
ian, acute myeloid leukemia, and Wilms’ tumor. Here we investigated GLIPR1 expression
in metastatic melanoma cell lines and tissue. GLIPR1 was variably expressed in metastatic
melanoma cells, and transcript levels correlated with degree of GLIPR1 promoter methy-
lation in vitro. Elevated GLIPR1 levels were correlated with increased invasive potential,
and siRNA-mediated knockdown of GLIPR1 expression resulted in reduced cell migration
and proliferation in vitro. Immunohistochemical studies of melanoma tissue microarrays
showed moderate to high staining for GLIPR1 in 50% of specimens analyzed. GLIPR1
staining was observed in normal skin in merocrine sweat glands, sebaceous glands, and
hair follicles within the dermis.
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INTRODUCTION
GLI pathogenesis-related 1 (GLIPR1) has been reported to act as a
tumor suppressor gene that is down-regulated in prostate cancer
(1–3). In contrast, GLIPR1 is up-regulated in glioma (4, 5) and
Wilms’ tumor (6) compared to normal tissue, and has recently
been shown to be differentially expressed in ovarian cancer cell
lines (7). GLIPR1 encodes a 266 amino acid (∼30 kDa) member
of the CAP superfamily (cysteine rich secretory proteins, antigen 5,
and pathogenesis-related 1 proteins) (8). The N-terminus of most
of the CAP proteins includes a putative signal peptide indicating
this protein is secreted or surface exposed. GLIPR1 is charac-
terized by a postulated signal peptide and a putative C-terminal
transmembrane domain (TMD) (5).
GLIPR1 has been reported to be regulated by p53 in prostate
cancer (1). Increased apoptosis, accompanied by decreased tumor
progression and metastasis were reported following adeno-viral
delivery of Glipr1 in an orthotopic model for metastatic prostate
cancer (9). Glipr1-mediated proapoptotic activity was also shown
to be related to the presence of the N-terminal signal peptide. Li et
al. showed that GLIPR1 up-regulation resulted in elevated reactive
oxygen species production, leading to apoptosis through activation
of the c-Jun–NH2 kinase signaling cascade (10). GLIPR1 has also
been shown to regulate growth, survival, and invasion of glioma
cells (11). Epigenetics studies have shown that hypermethylation
in the promoter region of GLIPR1 is responsible for the down-
regulation of GLIPR1 in prostate cancer (2). In addition, methy-
lation studies of GLIPR1 showed significant hypomethylation in
Wilms’ tumor relative to normal tissue (6). In the development of
malignant melanoma, epigenetic changes are emerging as impor-
tant factors where more than 70 hypermethylated genes have been
identified and hypomethylation occurs globally in tumor cells
[reviewed in (12)].
Despite a growing body of literature pointing to a role for
GLIPR1 in cancer, little is known of the normal function of
GLIPR1 and of how disruption might contribute to cancer ini-
tiation or progression. We identified GLIPR1 as part of a gene
expression signature that predicted invasive potential in melanoma
cell lines (13). Here we report on the role of GLIPR1 in melanoma
in more detail, and confirm that GLIPR1 is variably expressed
in melanoma cells, which is underpinned by differential pro-
moter methylation,and that GLIPR1 levels correlated with invasive
potential. We also show that GLIPR1 is variably expressed in
melanoma tissue samples, and can be detected in certain adnexal
structures of normal epidermis. We also show that GLIPR1 is
a glycosylated transmembrane protein transported to the cell
surface.
MATERIALS AND METHODS
CELL LINES
Melanoma cell lines used for this study were generated from
pathologically confirmed metastatic melanoma samples obtained
with ethical approval as previously described (14, 15) and
cultured in MEM-α (Invitrogen) supplemented with 0.1%
insulin-transferrin-sodium selenite (Roche) and 10% fetal bovine
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serum (FBS; Bio International, New Zealand). Glioma cell lines
U251 and SNB75 were obtained from the Developmental Ther-
apeutics Program, National Cancer Institute and cultured in
DMEM (Invitrogen) supplemented with 10% FBS. All new cell
lines were maintained at 37°C in a humidified atmosphere of
5% CO2. The NZM cell lines used for migration assays in this
study were chosen based on their classification as either having a
lower (NZM12, 15, 45) or higher (NZM9, 40) invasive potential
based on previously published transcript and phenotype profiling
(13). Given the established association in the literature between
elevated GLIPR1 levels and glioma progression, glioma cell lines
were included as comparative high GLIPR1 positive controls in
this study.
RNA ISOLATION AND REAL-TIME REVERSE TRANSCRIPTION
QUANTITATIVE PCR
Total RNA was extracted from cultured cells using RNeasy columns
(Qiagen) according to the manufacturer’s specification. Total
RNA (100 ng) was transcribed into cDNA using SuperScript III
Reverse Transcriptase (Invitrogen), primed with random hexam-
ers (Invitrogen) and oligo d(T) (Invitrogen) in a 20µL reaction
volume according to the manufacturer’s instructions. Transcript
abundance was measured using Platinum SYBR Green qPCR
SuperMix-UDG with ROX reference dye (Invitrogen) on an ABI
7300 Real-Time PCR System. Reverse transcription quantitative
PCR (RT-qPCR) reactions were performed in duplicate with 2.5 ng
template cDNA (RNA equivalent) per 20µL reaction and cor-
responding no-template controls. Cycling conditions were 50°C
for 2 min, 95°C for 2 min, then 40 cycles of 95°C for 15 s/60°C
for 1 min, followed by melting curve analysis. GLIPR1 abun-
dance was normalized to Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, zeta polypeptide (YWHAZ),
and Ubiquitin C (UBC) reference gene expression and expressed
relative to GLIPR1 levels in NZM15 (possessing the lowest level of
GLIPR1) using qBase software and the delta–delta-Cq method.
The following primers were used in RT-qPCR experiments.
GLIPR1 forward primer: AGT TCC GAT CAG AGG TGA AAC
C; GLIPR1 reverse primer: GCT TCA GCC GTG TAT TAT
GTG A; UBC forward primer: ATT TGG GTC GCG GTT CTT
G; UBC reverse primer: TGC CTT GAC ATT CTC GAT GGT
(RTPrimerDB ID 8); YWHAZ forward primer: ACT TTT GGT
ACA TTG TGG CTT CAA; YWHAZ reverse primer: CCG CCA
GGA CAA ACC AGT AT (RTPrimerDB ID 9) (16).
CELL LYSATE PREPARATION ANDWESTERN BLOTTING
Lysates were prepared by incubating cells for 30 min in
buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.5%
(w/v) sodium deoxycholate, 1% (w/v) nonyl phenoxylpoly-
ethoxylethanol (NP40), 0.1% (w/v) sodium dodecyl sulfate (SDS),
20× complete protease inhibitor (50µl; Roche), 1µM sodium
orthovanadate, and 1 mM phenylmethylsulfonyl fluoride (PMSF).
Protein concentration of the lysate was determined using a bicin-
choninic acid assay (BCA kit; Pierce Chemical Co.) according
to the manufacturer’s instructions. Total protein was resolved
by SDS-PAGE and electro transferred onto Bio Trace Polyvinyli-
dene Fluoride (PVDF) transfer membrane (Pall Corporation,
pore size 0.45µm). The PVDF membrane was blocked with
5% (w/v) non-fat milk powder in Tris-Buffered Saline Tween-
20 (TBST) followed by staining with mouse anti-GLIPR1 poly-
clonal antibody (Abnova, H00011010-A01) overnight at 4°C.
The specific bands were detected using goat anti-mouse IgG
horseradish peroxidase conjugated secondary antibody (Sigma-
Aldrich). Immuno-reactive bands were visualized using Super
Signal West Pico chemiluminescent substrate (Thermo Fisher Sci-
entific) and exposing the blots to imaging film (Kodak MXB
X-Ray film).
The quantification of non-saturated, developed western blots
was carried out using a GS-700 Imaging Densitometer (BioRad)
and the intensities of individual bands were quantified using
BioRad Quantity One software.
SMALL INTERFERING RNA TRANSFECTION
siRNA-mediated knockdown of GLIPR1 was performed using
reverse transfection with Lipofectamine RNAiMAX (Invitrogen)
and pre-designed siRNAs targeting GLIPR1 (ON-TARGETplus
SMARTpool, L-019819-00-0020, Dharmacon) according to the
manufacturer’s instructions, with a final siRNA concentration
of 10 nM. GLIPR1 knockdown was confirmed using RT-qPCR
(24 h) and western blotting (72 h) post-transfection. Negative
control experiments were performed using an ON-TARGETplus
Non-Targeting Pool (D-001810-10-20, Dharmacon). Sense-strand
GLIPR1 siRNA target sequences were:
GAG ACC AAG UGA AAC GUU A; GCU CAA GUA CCC UAA
UUU A; UAG CCU GGA UGG UUU CUU U; UGG CUG CGC
AGU UCA AUU U
ON-TARGETplus GAPD control siRNA was used as a pos-
itive control to assess transfection efficiency (D-001830-01,
Dharmacon).
CELL PROLIFERATION
Cell proliferation and viability was quantified using an MTT-based
cell proliferation kit (Roche) according to the manufacturer’s
instructions. Briefly, 2.5× 103 cells per well of a 96-well plate,
in a final volume of 100µl media were transfected with siRNA
(see above). The cells were grown at 37°C, 5% CO2, for 2, 4,
6, or 8 days after which they were treated with 10µl MTT and
incubated at 37°C for 4 h. The resulting formazan crystals were
then solubilized with 100µl solubilization solution and incubated
overnight at 37°C. The absorbance (570 nm) was then measured
with a microplate reader (Molecular Devices). Media was changed
every 3 days.
TRANSWELL MIGRATION AND INVASION ASSAY
Boyden chamber migration assays were carried out in 24-well
format using Transwell cell culture inserts with a polyethylene
terephthalate (PET) membrane filter and an 8µm pore size (BD
Biosciences). Cell suspension in 200µL media supplemented with
2% FBS (v/v) was added to the upper chamber (5× 105 cells/ml).
The lower chamber was filled with 600µl medium supplemented
with 10% (v/v) FBS as a chemoattractant. The cells were allowed to
migrate across the membrane for 24 h at 37°C, 5% CO2. After 24 h,
cells were rinsed with PBS and fixed with pre-chilled methanol for
10 min followed by rinsing with distilled H2O. Fixed cells were
stained with hematoxylin for 5–10 min at room temperature then
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rinsed with dH2O. Cells that remained on the top side of the mem-
brane were removed with a cotton swab, and the remaining cells
imaged using an Olympus IX71 inverted microscope. Twenty-five
random fields of view were captured per Transwell insert, and
the number of cells that had migrated to the bottom side of the
membrane was counted by using ImageJ software (17).
Invasion assays were carried out in a similar way using BioCoat
Matrigel invasion chambers (BD Biosciences) consisting of a BD
Falcon Cell Culture Insert with an 8µm pore PET membrane,
uniformly coated with BD Matrigel Matrix.
To investigate the effect of siRNA-mediated knockdown of
GLIPR1 on the migration or invasion of cells, 3× 104 cells/well
were transfected with siRNA targeting GLIPR1, or non-targeting
siRNA, for 24 h. Cells were trypsinized, pooled, and counted from
three to four wells 24 h post-transfection, and 1× 105 cells were
seeded per insert for migration or invasion assays as described
above.
METHYLATION
GLIPR1 promoter methylation status was analyzed by using
bisulfite genomic sequencing. Genomic DNA was isolated from
cultured cells using a Purelink Genomic DNA kit (Invitrogen)
according to the manufacturer’s instructions. Genomic DNA
(300 ng) was bisulfite-converted and purified by using EZ DNA
Methylation-Gold (Zymo Research) according to the manufac-
turer’s instructions. One microliter of bisulfite-converted DNA
was amplified by using two rounds of PCR,purified with a Purelink
PCR Purification kit (Invitrogen), then visualized and quanti-
tated by using an Agilent 2100 Bioanalyzer. Purified PCR products
were then submitted to the Genetic Analysis Services, University
of Otago, for Sanger sequencing. DNA methylation analysis was
performed using BiQ Analyzer v2.00 (18). We amplified a 320 bp
region using primers for amplification and sequencing of GLIPR1
from bisulfite-treated DNA previously published by Muller et al.
(19). This region extends from−104 to−424 of the GLIPR1 trans-
lation start site, and corresponds to the CpG’s referred to as “A–D”
in (2). The primers were: forward, TTA TTA TGT GTT GAT ATG
ATT TTA AAA AG; reverse AAC CCA CAA CTT TAC AAA CC
TAA CC.
TISSUE SAMPLES AND ARRAYS
Skin specimens used in this study were archival human tissue spec-
imens maintained by Healthlab Otago, Dunedin Public Hospital,
Dunedin, New Zealand. All specimens were ethically consented for
use under approval MEC/07/05/065 (with written informed con-
sent from Multi-Region Ethics Committee, Ministry of Health,
New Zealand). Melanoma tissue microarrays were purchased
from US Biomax, Inc. Melanoma and nevi tissue microarrays
(catalog number ME1001) consisted of 56 cases of malignant
melanoma, 20 cases of metastatic melanoma, and 24 cases of
benign nevus.
IMMUNOHISTOCHEMISTRY
Five micrometer paraffin-embedded tissue sections were de-waxed
in xylene and rehydrated through a series of graded ethanols.
Endogenous peroxidase activity of the tissue was then quenched
with 3% (v/v) H2O2 in methanol for 10 min. Slides were washed
with distilled water prior to microwave-mediated antigen retrieval
in 10 mM sodium citrate with 0.05% Tween-20, pH 6.0 for 15 min.
Cooled sections were rinsed in PBS, blocked with 10% normal
goat serum in PBS for 30 min and incubated with a mouse poly-
clonal anti-GLIPR1 antibody (Abnova, A01; 1:200) overnight at
4°C. The signal was subsequently detected using Vectastain Elite
ABC peroxidase-based detection system (Vector Laboratories). For
melanoma and skin specimens NovaRED™ (Vector Laboratories)
was used for visualization of immuno-reactivity to distinguish
from melanin. To verify the specificity of the immuno-reactions,
some sections were incubated in normal goat serum instead of
primary antibody. Negative control incubations using the same
secondary antibody, but omitting the primary antibody were
also carried out and showed negative staining. Validation of the
antibodies is provided in supplementary material (Figure S1 in
Supplementary Material).
All tissue sections were observed and photographed using a
Zeiss MC100 camera coupled to a Zeiss Axioplan universal micro-
scope at a power of 200× or 400×. Randomly selected two to three
microscopic measuring fields were analyzed for staining and iden-
tification of specific cell types. At least 100 cells were counted per
microscopic field visualized.
STATISTICAL ANALYSIS
The results are presented as the average values± standard error of
mean (SEM). Data were analyzed using ANOVA and a Student’s t
test (with unequal variances). All graphs were generated by using
Prism 4 (GraphPad Software, Inc.).
RESULTS
GLIPR1 EXPRESSION CORRELATED WITH PROMOTER METHYLATION
AND INVASIVE POTENTIAL IN VITRO
GLIPR1 levels measured using RT-qPCR corresponded with the
relative levels reported by previous microarray profiling of NZM
cells lines (13), with NZM9 and 40 having relatively higher
GLIPR1 abundance compared to NZM12, 15, and 45. Among
the five melanoma cell lines, NZM15 cells had the lowest level
of GLIPR1 expression and was used as the baseline reference.
The NZM40 cells had the highest GLIPR1 expression (∼66-
fold higher expression relative to NZM15, Figure 1A). NZM9
cells showed a greater GLIPR1 expression level than that seen
in U251 cells which were used as a positive control (∼43 and
24-fold higher than NZM15 respectively). SNB75 cells previ-
ously shown to have elevated GLIPR1 expression (5), showed
the highest expression levels within the melanoma and glioma
cells tested, with 110-fold higher abundance relative to NZM15
cells. Consistent with the RT-qPCR results, NZM9, NZM40,
U251, and SNB75 cells showed higher amounts of GLIPR1 pro-
tein, whereas GLIPR1 was undetectable in NZM12, NZM15, and
NZM45 after exposure for 5 min and only a very small amount
was evident following exposure overnight (Figure 1B). Vari-
able GLIPR1 transcript levels were associated with differences
in promoter methylation in a panel of melanoma cell lines of
known invasive potential (Figure 1C; Figure S2A in Supplemen-
tary Material), with increasing promoter methylation associated
with decreasing GLIPR1 abundance (r2= 0.82, p= 0.037). When
additional cell lines from a previous study (13) were included
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FIGURE 1 | GLIPR1 expression and promoter methylation in melanoma
cells. (A) Relative mRNA transcript levels of GLIPR1 in different melanoma
and glioma cells were quantified by RT-qPCR, normalized to reference
genes YWHAZ and UBC, and reported relative to levels in NZM15. Results
are mean of three independent experiments and error bars indicate SEM.
(B) GLIPR1 protein levels in different melanoma and glioma cell lines were
determined by western blotting with each lane loaded with 100µg of total
protein; the top GLIPR1 blot and β-tubulin loading control (bottom) was
exposed for 5 min, and the center GLIPR1 blot exposed overnight. Two
separate experiments gave similar results. (C) Summary of bisulfite
sequencing data showing GLIPR1 CpG promoter methylation status for
melanoma cell lines with known invasive potential (this study). NZM09 and
NZM40 are strongly invasive compared to the remaining cell lines. Lollipops
represent individual CpG dinucleotides within a CpG island in the GLIPR1
promoter. DNA from three different vials of each NZM cell line was
sequenced at least twice on both strands. White, unmethylated; black,
methylated; black/white, hemimethylated.
in the analysis the correlation improved (r2= 0.83, p= 0.002;
Figures S2B,C in Supplementary Material). Demethylation treat-
ment with 5-azacytidine caused increased transcript abundance
FIGURE 2 | GLIPR1 cell migration and invasion. Frequency with which
melanoma and glioma cells cross a pored membrane by (A) migration or
(B) invasion was assessed by microscope after 24 h. Number of migrating
or invading cells was calculated by counting the number of cells per field of
view in 25 microscopic fields per well. Data shown as the average number
of cells per field of view±SEM from three (A) or two (B) independent
experiments respectively. (C) GLIPR1 transcript levels were significantly
higher in an independent panel of cell lines with experimentally validated
invasive potential (20).
in NZM15, NZM12, and NZM45 (Figure S3 in Supplementary
Material).
Having confirmed variable expression of GLIPR1, we then
chose to investigate the relationship between GLIPR1 abundance
and invasion in melanoma and glioma cells. In vitro cell migra-
tion and invasion was positively correlated with endogenous
GLIPR1 expression levels (r2= 0.94 and r2= 0.91 respectively,
Figures 2A,B; Figure S4 in Supplementary Material) suggest-
ing a role for GLIPR1 in the migratory or invasive potential of
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melanoma cells. Cells with the highest GLIPR1 expression (NZM9,
NZM40, U251, SNB75) showed the highest number of migrating
and invading cells (Figures 2A,B). Conversely, cells with relatively
low levels of GLIPR1 (NZM12, NZM15, NZM45) showed little to
no migrating cells and no detectable invasion. The total number
of cells invading through the Matrigel matrix was less than in the
absence of matrix, but the overall trend of invasion was similar to
that of migration: cell lines with highest GLIPR1 levels (NZM40
and SNB7) showed the highest invasion. Increased GLIPR1 tran-
script levels were also associated with increased invasion in an
independent set of publically available microarray data generated
from melanoma cell lines with experimentally validated invasive
potential (Figure 2C) (20).
GLIPR1 KNOCKDOWN CAUSED REDUCED CELL INVASION AND
PROLIFERATION
To further investigate the relationship between GLIPR1 expression
and cell migration and invasion, GLIPR1 expression was decreased
using siRNA. siRNA-mediated knockdown of GLIPR1 resulted in
a significant decrease in the number of melanoma and glioma cells
migrating across the membrane relative to non-targeting controls
(Figure 3; Figure S5 in Supplementary Material). We used glioma
cell lines in which GLIPR1 had previously been shown to mod-
ulate invasive behavior (11) as positive controls to compare with
melanoma cell lines in our in vitro invasion assays. SNB75 glioma
cells, with the highest pre-knockdown migration rate, showed
about a 50% decrease in cell migration 24 h after GLIPR1 knock-
down (Figure 3B). Similarly, the high GLIPR1-expressing cell lines
NZM40, NZM9 and U251 showed a 20–30% decrease in migra-
tion compared to non-targeting controls. Cells with lower GLIPR1
levels (NZM12, NZM15) showed no measurable change in the
already small number of cells migrating across the membrane after
knockdown which reflects the intrinsically weak invasive potential
of these cells.
GLIPR1 knockdown led to a significant reduction in the num-
ber of cells invading through Matrigel matrix (Figure 3C). The
largest decrease in invasion was observed in NZM9 cells (∼38%)
followed by NZM40 (30%) and SNB75 (24%) cells, with U251
cells (8%) showing a small but significant reduction in cell invasion
(Figure 3C). Overall, the results of our Transwell assays and knock-
down experiments support the notion that GLIPR1 is involved in
mediating the invasive potential of melanoma cell lines.
FIGURE 3 | GLIPR1 siRNA knockdown decreases cellular invasion and
proliferation. (A) GLIPR1 protein levels following knockdown were
determined by western blotting (40µg of total protein per lane) from cells
72 h following transfection with siRNA. GLIPR1 knockdown with siGLI (+)
and control treatment with non-targeting siRNA siNT (−) are indicated
above gel. Low levels of endogenous GLIPR1 prevented assessment of the
extent of knockdown in NZM15, NZM12, and NZM45 by western blotting.
Relative migration (B) and invasion (C) of cells across the membrane of
transwell inserts was measured 24 h after siGLI. Data shown as the
average number of cells per field of view±SEM from three (B) or two (C)
independent experiments. Error bars indicate SEM; *p<0.005,
**p<0.001. No migration was observed for NZM45 (Figure 2A) and no
invasion was seen for NZM45, NZM12, or NZM15 (Figure 2B). (D) Cell
proliferation was quantified using MTT-based colorimetric assay. Results are
mean of two independent experiments, n=4. Results in (D) are shown as
data for cells 4 days after transfection with siGLI relative to data for cells
transfected with siNT. Results for (B,C) are shown for cells 24 h following
transfection.
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siRNA-mediated knockdown of GLIPR1 resulted in a 10–22%
decrease in proliferation in melanoma cells compared to 31 and
25% decrease for U251 and SNB75 glioma cells respectively, 4 days
after transfection (Figure 3D). Reduced proliferation in glioma
cell lines was observed by Rosenzweig et al. (11) who also reported
that silencing of GLIPR1 induced apoptosis in some glioma cells.
However, we saw no evidence of increased apoptosis or cell cycle-
related growth arrest in any of the glioma and melanoma cells
tested in this study (data not shown).
CELLULAR LOCALIZATION OF GLIPR1
To help understand how GLIPR1 could mediate invasion we exam-
ined cellular localization. GLIPR1 contains a predicted signal
peptide and C-terminal TMD suggesting it may be translocated to
the endoplasmic reticulum (ER) and trafficked to the cell surface as
an integral membrane protein. In vitro translation assays showed
GLIPR1 is processed to a higher molecular weight form in the pres-
ence of ER membranes (Figure S6A in Supplementary Material).
This higher molecular weight form is sensitive to Endoglycosi-
dase H digestion, indicating that it is glycosylated (Figure S6B in
Supplementary Material). GLIPR1 segregates in the pellet fraction
upon sodium carbonate extraction (Figure S6C in Supplementary
Material), which confirms that it is integrated in the membrane.
The higher molecular weight glycosylated GLIPR1 is protected
from protease digestion in the absence of detergent (Figure S6D
in Supplementary Material). Taken together these results indicate
that GLIPR1 has a functional signal peptide and TMD, and is
translocated into the ER where it is glycosylated at a site in its ER-
lumen exposed soluble domain. Cell surface biotinylation assays
in GLIPR1-expressing NZM9 cells demonstrated that GLIPR1 is
present at the cell surface (Figure S7 in Supplementary Material).
GLIPR1 EXPRESSION IN MELANOMA AND SKIN TISSUE
Having demonstrated a relationship between GLIPR1 expres-
sion and migration/invasion in melanoma cell lines, we investi-
gated GLIPR1 expression in melanoma and skin tissue samples.
Immunohistochemical staining of malignant melanoma tissue
samples showed variable expression of GLIPR1 (Figures 4A–C) in
a similar fashion to the NZM cell lines. Of the 76 melanoma speci-
mens analyzed, 50% showed moderate to high immuno-reactivity
(++ and +++) for GLIPR1. The other 50% of the specimens
(38/76) showed either no (26/76) or low (12/76) staining for
GLIPR1. However, unlike glioma, there was no obvious relation-
ship between GLIPR1 positivity and melanoma progression. In
normal skin, all layers of the epidermis except for the stratum
corneum were immuno-positive for GLIPR1 (Figure 5A). Cells of
the basal layer showed positive staining for GLIPR1 (Figure 5A,
red). Most of the fibro-elastic tissue in the dermal layer of skin was
found to be immuno-negative for GLIPR1. However, merocrine
sweat glands, sebaceous glands, and hair follicles within the dermis
were found to be immuno-positive for GLIPR1 (Figures 5B–D).
DISCUSSION
GLIPR1 transcript and protein have been reported in various tis-
sues including heart, lung, liver, spleen, skin, colon, pancreas, lym-
phocytes, muscle, bone marrow, placenta, adrenal gland, prostate,
glioma, and prostate cancer (5, 11, 21). More recently, GLIPR1
FIGURE 4 | GLIPR1 staining in malignant melanoma. GLIPR1
immuno-staining in (A) malignant melanoma of the heel (+, low staining
intensity), (B) malignant melanoma of the pate/crown (++, moderate
staining intensity), and (C) malignant melanoma of the thumb (+++, high
staining intensity). GLIPR1 immuno-positive regions were stained with
NovaRED. All images were photographed at a power of 200×. Scale
bar=50µm. Samples shown are from Melanoma tissue microarrays (US
Biomax, Inc.).
has been found to be differentially expressed in ovarian cancer
and acute myeloid leukemia (7, 22). However, GLIPR1 expression
analysis in melanoma has not been previously reported. Using RT-
qPCR and western blots we found variable expression of GLIPR1
mRNA and protein in different metastatic melanoma cell lines
with two melanoma cell lines having similar levels to glioma
cell lines previously reported as having high GLIPR1 expression
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FIGURE 5 | Immunohistochemical staining of GLIPR1 in skin
specimens. Immuno-reactive cells of normal skin (A), sweat glands (B),
sebaceous glands, (C), hair follicles (D). Skin specimens (A–C) were
stained with NovaRED to give a red color for GLIPR1 immuno-positive
regions, while hair follicles (D) were stained with DAB to give brown color
for GLIPR1. Cell nuclei are stained blue with hematoxylin. Inset images
show negative control reacted with the non-specific goat serum instead of
anti-GLIPR1 antibody. Lack of brown staining in the negative control
indicates this is due to GLIPR1 and not melanin. All images were
photographed at a power of 400×.
(Figures 1A,B). These data add to the growing number of can-
cer cell types in which GLIPR1 has been reported to be variably
expressed.
Epigenetic modulation of GLIPR1 expression by promoter
methylation has been reported previously in prostate cancer,
glioma, and Wilms’ tumors, and we show that it is also the case in
melanoma cells in the samples tested, with decreasing promoter
methylation associated with increasing levels of GLIPR1. Our
study focused on metastatic melanoma cells. Whether GLIPR1
promoter methylation is dynamic during disease progression
or shows higher or lower levels of methylation in metastatic
melanoma cells compared to normal melanocytes, benign nevi
and primary melanoma remains unknown and requires further
investigation.
We investigated the relationship between endogenous GLIPR1
levels and migration and invasion potential in vitro, which revealed
that melanoma cells with higher endogenous GLIPR1 levels dis-
played significantly greater migration and invasion capability than
cells with relatively lower levels of GLIPR1. siRNA-mediated
knockdown of GLIPR1 inhibited migration and invasion in
melanoma cell lines (Figures 3B,C). The low level of migration
and complete lack of invasion in melanoma cells with relatively
lower GLIPR1 levels (NZM15, NZM12, and NZM45) suggests
that a threshold level of GLIPR1 expression may be present in
melanoma cells with a strongly invasive phenotype as GLIPR1
levels in NZM9, NZM40, U251, and SNB75 cells after siRNA-
mediated knockdown were still higher than that in untreated and
weakly invasive NZM15, NZM12, and NZM45 cells. Overexpres-
sion of GLIPR1 has previously been shown to increase invasion
of several glioma cell lines (11), and is consistent with our find-
ings in melanoma cells suggesting GLIPR1 acts as an oncoprotein
rather than a tumor suppressor in melanoma. GLIPR1 knockdown
caused a modest but reproducible decrease in proliferation in both
melanoma and glioma cells, suggesting that GLIPR1 may play a
role in cell growth at some level. It is possible that the reduced inva-
sion we observed after GLIPR1 knockdown was a consequence of
the observed reduction in proliferation.
We demonstrated for the first time that GLIPR1 contains a
functional signal peptide and TMD (Figure S6 in Supplementary
Material). We confirm that it is a glycoprotein, most likely at the
predicted glycosylation site at asparagine 92 (5), which is shown
by homology modeling of GLIPR1 to be on the surface of the pro-
tein (data not shown). Glycosylation was also seen in the recent
expression and structural studies by Asojo and co-workers (23,
24). GLIPR1 is translocated to the cell surface where its soluble
N-terminal domain will be exposed to the extracellular space. The
exposure of GLIPR1’s soluble domain to the extracellular matrix
is consistent with a role of GLIPR1 in invasion and migration.
Future investigations as to whether GLIPR1 possesses proteolytic
activity as displayed by another member of the CAP family (25)
would prove invaluable and provide insight as to whether such an
activity is directly associated with the cell invasion and migration
properties similar to that of matrix metalloproteases.
The present study characterized GLIPR1 expression by
immunohistochemistry in normal and cancerous skin. Previously,
mRNA levels of GLIPR1 transcripts in skin have been reported as
very low or undetectable (11, 21). Immunohistochemistry showed
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GLIPR1 was detectable in normal skin (Figure 5) within cer-
tain tissues such as epithelial cells of epidermis, sebaceous glands,
merocrine sweat glands, and hair follicles. Immunohistochemi-
cal staining of melanoma tissues confirmed variable expression of
GLIPR1, similar to that observed in NZM cell lines, with almost
an equal proportion of melanoma specimens expressing relatively
higher or relatively lower levels of GLIPR1. It does not appear that
GLIPR1 levels are uniformly elevated with increasing melanoma
stage, which is again consistent with GLIPR1 being sensitive to
dynamic gene expression changes that are associated with the pos-
tulated phenotype switching capacity of melanoma cells during
disease progression. Although we demonstrated variable GLIPR1
staining in melanoma tissue microarray samples, these samples
lacked clinical information, so the clinical significance of variable
GLIPR1 expression remains unknown. A survey of publically avail-
able array data shows that GLIPR1 levels are variable in melanoma
(13), which is in agreement with our observations in this study.
However, there is little useful published melanoma array data
that includes patient information to determine if GLIPR1 tran-
script abundance is correlated with clinical outcome. We analyzed
GLIPR1 levels in the study of metastatic melanoma samples by
Bogunovic and colleagues (26), which includes clinical data, and
found that elevated GLIPR1 levels were significantly positively
correlated with survival (Figure S8 in Supplementary Material).
Given elevated GLIPR1 levels are part of a multi-gene expression
signature that is associated with a phenotypic balance between
invasive and proliferative states in melanoma, we speculate that
metastatic melanomas with an invasive phenotype may prolifer-
ate more slowly (according to the phenotype switching model),
and thus offer a survival advantage to the patient, compared to
less invasive but more rapidly proliferating tumors. Further data
are required to confirm this observation. Yang and co-workers
(27) identified GLIPR1 as part of a group of extracellular matrix-
related genes involved in a melanocyte growth arrest program,
which further implicates GLIPR1 as having a potential role in the
dynamics of melanocyte biology via interaction with the extra-
cellular microenvironment. Further investigation is required to
clarify this.
The MITF and POU3F2 (BRN2) transcription factors have
been reported to be inversely correlated in melanoma cells (28),
are both key markers of the phenotype switching model of inva-
sive potential [reviewed in (29)], and are both possible regulators
of GLIPR1. GLIPR1 is inversely correlated with MITF in NZM cell
lines (13), suggesting that perhaps MITF might negatively regulate
GLIPR1. However, the evidence to support this is lacking: there are
no MITF binding sites in the GLIPR1 promoter (not shown), and
recent studies by others – although not taking epigenetic silenc-
ing into account – did not identify GLIPR1 as a direct target of
either MITF or POU3F2 in melanoma cells (30–32). Based on our
GLIPR1 promoter methylation data, we speculate that perhaps
genome-wide epigenetic re-programing can occur in melanoma
cells, to which GLIPR1 is sensitive, and that is associated with
phenotype switching mechanisms in melanoma cells.
Malignant melanoma is an aggressive and unpredictable cancer.
Currently there is no cure for metastatic melanoma, and no way
of determining which patients will respond to current treatment
options. The mechanisms underlying melanoma progression and
resistance to therapeutic agents are not well understood. There
are few treatment options once metastasized, and new biomark-
ers that aid diagnosis, predict clinical outcome, and suggest new
therapies are required. Based on the data presented here, future
studies will focus on identifying whether GLIPR1 levels and/or
promoter methylation status may be a clinically beneficial marker
of metastatic melanoma phenotype.
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